EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Robust Alpha Spending for Unstable Data

Ivair R Silva iD, Judith C Maro iD

Statistics in Medicine · 2026

DOI: 10.1002/sim.70760 ↗

At a glance

Journal article in Statistics in Medicine, 2026. Written by Ivair R Silva and 1 co-authors. Institution: Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Major MEDLINE topics: Randomized Controlled Trials as Topic. 22 references. The full text is freely available (open access, CC BY 4.0). Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Robert H. Ebert Career Development Award.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Sequential hypothesis testing has been used in randomized clinical trials and in monitoring adverse events after vaccination. Typically, the presumption is that all data that have been previously used in the sequential analysis remain the same, and only new data are added. We call this the “anchoring” assumption. In prelicensing randomized trials, enrollment goals are set based on these sequential hypothesis tests so that a trial may stop if a drug proves either too hazardous or, conversely, so beneficial that it would be unethical to deny the treatment to others. However, in monitoring adverse events after vaccination, data are mostly “secondary use,” or real‐world data. That is, these data are not gathered for research, but are clinical data that have been repurposed for observational vaccine safety surveillance. As such, the counts of exposed persons and adverse events may be subject to revisions over time. These data changes directly challenge the anchoring assumption upon which most sequential hypothesis testing depends. If these data changes are discovered prior to subsequent hypothesis tests, it is unclear how to account for these changes in subsequent tests. We introduce a solution: “robust alpha spending” to protect overall type I error probability, statistical power, and surveillance time from low‐level data instability present in secondary use data sources used for adverse event monitoring.

Subjects

MeSH terms (MEDLINE)

Randomized Controlled Trials as TopicHumansData Interpretation, StatisticalVaccinesVaccinationModels, StatisticalProduct Surveillance, Postmarketing

Author keywords

adverse eventsexpected time to signalpost‐market vaccine safety surveillancerelative risksequential test

Substances

Vaccines

Authors and institutions

  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Computer Department, Federal University of Ouro Preto, Ouro Preto, Brazil.
  • Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.

ORCID profiles: Ivair R Silva, Judith C Maro

Funding

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Robert H. Ebert Career Development Award

Cite

APA

Silva, I. R., & Maro, J. C. (2026). Robust Alpha Spending for Unstable Data. Statistics in Medicine. https://doi.org/10.1002/sim.70760

Vancouver

Silva IR, Maro JC. Robust Alpha Spending for Unstable Data. Statistics in Medicine. 2026. doi:10.1002/sim.70760

BibTeX
@article{Silva2026,
  author = {Silva, Ivair R and Maro, Judith C},
  title = {Robust Alpha Spending for Unstable Data},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70760}
}
Start for free →